Published in:
01-09-2014 | Hepatobiliary-Pancreas
Spectral CT evaluation of interstitial brachytherapy in pancreatic carcinoma xenografts: preliminary animal experience
Published in: European Radiology | Issue 9/2014
Login to get accessAbstract
Objectives
We sought to evaluate the capability of spectral CT to detect the therapeutic response to 125I interstitial brachytherapy in a pancreatic carcinoma xenograft nude mouse model.
Methods
Twenty mice bearing SWl990 human pancreatic cancer cell xenografts were randomly separated into two groups: experimental (n = 10; 1.0 mCi) and control (n = 10; 0 mCi). After a two-week treatment, spectral CT was performed. Contrast-to-noise ratio (CNR) and iodine concentration (IC) in the lesions were measured and normalized to the muscle tissue, and nIC CD31 immunohistochemistry was used to measure microvessel density (MVD). The relationships between the nIC and MVD of the tumours were analysed.
Results
The nIC of the experimental group was significantly lower than that of the control group during the multiphase examination. A significant difference in the MVD was observed between the two groups (P <0.001). The nIC values of the three-phase scans have a certain positive correlation with MVD (r = 0.57, p < 0.0001; r = 0.48, p = 0.002; r = 0.63, p = 0.0017 in the 10, 25, and 60 s phase, respectively).
Conclusions
Spectral CT can be a useful non-invasive imaging modality in evaluating the therapeutic effect of 125I interstitial brachytherapy to a pancreatic carcinoma.
Key Points
• Spectral CT offers opportunities to assess therapeutic response in pancreatic cancer cases.
• Spectral CT findings correlated with vascular changes associated with 125I seed implantation.
• Spectral CT with monochromatic imaging removed most 125I seed artefacts.